CYTOKINETICS STARTS SB-743921 TRIAL

Cytokinetics has launched a Phase I/II clinical trial of its second kinesin spindle protein (KSP) inhibitor, SB-743921, in patients with non-Hodgkin's lymphoma or NHL. Cytokinetics is conducting this clinical trial in order to expand the development activities for SB-743921, based on a recently amended agreement with GlaxoSmithKline.

The trial is an open-label, non-randomized study to investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of SB-743921. The objective of the Phase I portion of the clinical trial is to identify the maximum tolerated dose of SB-743921.